Montréal, Quebec, Canada Amorchem appeared to be the VC, which was created in 2011. The fund was located in North America if to be more exact in Canada. The leading representative office of defined VC is situated in the Montru00e9al.
Deals in the range of 1 - 5 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year. The important activity for fund was in 2018. Considering the real fund results, this VC is 47 percentage points more often commits exit comparing to other organizations.
Among the most popular portfolio startups of the fund, we may highlight Semathera, Inversago Pharma. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Canada. The fund has exact preference in some founders of portfolio startups. Among the most successful fund investment fields, there are Pharmaceutical, Biotechnology.
The usual cause for the fund is to invest in rounds with 4 partakers. The meaningful sponsors for the fund in investment in the same round are Accel-Rx Health Sciences Accelerator, Tarnagulla Ventures, Senju Pharmaceutical.
This organization was formed by Elizabeth Douville, Inu00e8s Holzbaur.
Related Funds
| Fund Name | Location |
| Baron Capital Management | Arizona, Scottsdale, United States |
| Endo Investors | California, Los Angeles, United States |
| Goodpatch | Japan, Tokyo |
| Greenstone Investments | Auburn Hills, Michigan, United States |
| Indigo Investment Corporation | Chicago, Illinois, United States |
| Nosara Capital | England, London, United Kingdom |
| Summer VC | - |
| UK Trade & Investment (UKTI) | England, London, United Kingdom |
| WaterStart Capital | Atlanta, Georgia, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Inversago Pharma | $75M | 17 Oct 2022 | Montreal, Quebec, Canada | ||
Giiant Pharma | $11M | 21 May 2021 | Montréal, Quebec, Canada | ||
Inversago Pharma | $35M | 08 Sep 2020 | Montreal, Quebec | ||
Inversago Pharma | $7M | 25 Jul 2018 | Montreal, Quebec, Canada | ||
SpecificiT Pharma | 11 Sep 2017 | Montreal, Quebec, Canada |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Inversago Pharma | $75M | 17 Oct 2022 | Montreal, Quebec, Canada | ||
Giiant Pharma | $11M | 21 May 2021 | Montréal, Quebec, Canada | ||
Inversago Pharma | $35M | 08 Sep 2020 | Montreal, Quebec | ||
Inversago Pharma | $7M | 25 Jul 2018 | Montreal, Quebec, Canada | ||
SpecificiT Pharma | 11 Sep 2017 | Montreal, Quebec, Canada |
